$BJDX

Bluejay Diagnostics, Inc.

CIK:0001704287|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 1,437,806	$ 889,896	$ 2,249,643	$ 1,674,696
General and administrative	911,318	1,095,465	2,038,312	2,199,582
Total operating expenses	2,349,124	1,985,361	4,287,955	3,874,278
Operating loss	(2,349,124)	(1,985,361)	(4,287,955)	(3,874,278)
Other income:
Interest income	24,829	29,254	43,688	47,055
Other income (expense), net	282	(497)	1,013	6,184
Total other income, net	25,111	28,757	44,701	53,239
Net loss	$ (2,324,013)	$ (1,956,604)	$ (4,243,254)	$ (3,821,039)
Net loss per share – Basic	$ (1.12)	$ (5.64)	$ (2.77)	$ (15.75)
Net loss per share – Diluted	$ (1.12)	$ (5.64)	$ (2.77)	$ (15.75)
Weighted average common shares outstanding – Basic	2,079,263	346,780	1,531,999	242,641
Weighted average common shares outstanding – Diluted	2,079,263	346,780	1,531,999	242,641

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,243,254)	$ (3,821,039)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	55,956	36,143
Stock-based compensation expense		(251)
Amortization of right-of-use asset	43,999	54,105
Write-off and impairment of property and equipment	2,880	495
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	72,986	291,460
Other non-current assets	1,644	13,093
Accounts payable	459,834	(36,305)
Accrued expenses and other current liabilities	517,399	223,387
Net cash used in operating activities	(3,088,556)	(3,238,912)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(161,762)
Proceeds from sale of property and equipment	3,675
Net cash used in investing activities	(158,087)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and pre-funded warrants, gross	8,624,835	3,846,692
Issuance costs related to issuance of common stock	(942,262)	(464,670)
Proceeds from exercise of prefunded warrants	232
Payment of finance lease	(2,121)	(1,979)
Net cash provided by financing activities	7,680,684	3,380,043
Increase in cash and cash equivalents	4,434,041	141,131
Cash and cash equivalents, beginning of period	5,164,875	4,301,945
Cash and cash equivalents, end of period	$ 9,598,916	$ 4,443,076

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 9,598,916	$ 5,164,875
Prepaid expenses and other current assets	202,971	275,957
Assets held for sale	13,065	22,770
Total current assets	9,814,952	5,463,602
Property and equipment, net	1,643,397	1,534,441
Operating lease right-of-use assets	69,290	113,289
Other non-current assets	6,261	7,905
Total assets	11,533,900	7,119,237
Current liabilities:
Accounts payable	674,089	214,255
Operating lease liability, current	73,444	100,000
Accrued expenses and other current liabilities	1,369,108	804,942
Total current liabilities	2,116,641	1,119,197
Operating lease liability, non-current		20,211
Other non-current liabilities	2,419	4,540
Total liabilities	2,119,060	1,143,948
Commitments and Contingencies (See Note 10)
Stockholders’ equity:
Common stock, $0.0001 par value; 250,000,000 shares authorized; 1,983,684 and 604,534 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	198	60
Additional paid-in capital	55,175,163	47,492,496
Accumulated deficit	(45,760,521)	(41,517,267)
Total stockholders’ equity	9,414,840	5,975,289
Total liabilities and stockholders’ equity	$ 11,533,900	$ 7,119,237